Business Description
Samsung BioLogics Co Ltd
ISIN : KR7207940008
Compare
Compare
Traded in other countries / regions
207940.Korea IPO Date
2016-11-10Description
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from its subsidiary, Samsung Bioepis, which it acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.21 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 0.97 | |||||
Interest Coverage | 15.05 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.68 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 43.9 | |||||
3-Year EBITDA Growth Rate | 55.1 | |||||
3-Year EPS without NRI Growth Rate | 48.7 | |||||
3-Year FCF Growth Rate | 114.3 | |||||
3-Year Book Growth Rate | 26.2 | |||||
Future 3-5Y EPS without NRI Growth Rate | 16.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 14.29 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.72 | |||||
9-Day RSI | 37.35 | |||||
14-Day RSI | 38.99 | |||||
6-1 Month Momentum % | -1.97 | |||||
12-1 Month Momentum % | 0.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.21 | |||||
Quick Ratio | 0.63 | |||||
Cash Ratio | 0.44 | |||||
Days Inventory | 458.77 | |||||
Days Payable | 32.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.1 | |||||
Shareholder Yield % | 0.72 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 47.96 | |||||
Operating Margin % | 29.16 | |||||
Net Margin % | 22.84 | |||||
FCF Margin % | 22.93 | |||||
ROE % | 9.36 | |||||
ROA % | 5.56 | |||||
ROIC % | 6.64 | |||||
ROC (Joel Greenblatt) % | 27.5 | |||||
ROCE % | 10.3 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 57.8 | |||||
Forward PE Ratio | 52.08 | |||||
PE Ratio without NRI | 57.71 | |||||
Shiller PE Ratio | 96.76 | |||||
Price-to-Owner-Earnings | 41.3 | |||||
PEG Ratio | 1.46 | |||||
PS Ratio | 13.2 | |||||
PB Ratio | 5.17 | |||||
Price-to-Tangible-Book | 12.26 | |||||
Price-to-Free-Cash-Flow | 57.56 | |||||
Price-to-Operating-Cash-Flow | 31.56 | |||||
EV-to-EBIT | 41.47 | |||||
EV-to-Forward-EBIT | 39.44 | |||||
EV-to-EBITDA | 29 | |||||
EV-to-Forward-EBITDA | 27.65 | |||||
EV-to-Revenue | 13.11 | |||||
EV-to-Forward-Revenue | 11.93 | |||||
EV-to-FCF | 57.18 | |||||
Price-to-Projected-FCF | 5.97 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.31 | |||||
Price-to-Graham-Number | 5.61 | |||||
Earnings Yield (Greenblatt) % | 2.41 | |||||
FCF Yield % | 1.74 | |||||
Forward Rate of Return (Yacktman) % | 20.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Samsung BioLogics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 3,920,570.047 | ||
EPS (TTM) (â‚©) | 12578 | ||
Beta | 0.45 | ||
Volatility % | 21.71 | ||
14-Day RSI | 38.99 | ||
14-Day ATR (â‚©) | 13255.450243 | ||
20-Day SMA (â‚©) | 741200 | ||
12-1 Month Momentum % | 0.4 | ||
52-Week Range (â‚©) | 668000 - 880000 | ||
Shares Outstanding (Mil) | 71.17 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Samsung BioLogics Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Samsung BioLogics Co Ltd Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Samsung BioLogics Co Ltd Frequently Asked Questions
What is Samsung BioLogics Co Ltd(XKRX:207940)'s stock price today?
The current price of XKRX:207940 is â‚©727000.00. The 52 week high of XKRX:207940 is â‚©880000.00 and 52 week low is â‚©668000.00.
When is next earnings date of Samsung BioLogics Co Ltd(XKRX:207940)?
The next earnings date of Samsung BioLogics Co Ltd(XKRX:207940) is 2024-07-12 Est..
Does Samsung BioLogics Co Ltd(XKRX:207940) pay dividends? If so, how much?
Samsung BioLogics Co Ltd(XKRX:207940) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |